Alkermes is poised to complete its acquisition of Avadel Pharmaceuticals in Q3 2024, creating a fully integrated biopharma with a dedicated sleep medicine franchise. The deal, structured as a cash-and-stock transaction, brings in FT218, a once-nightly formulation of sodium oxybate expected to generate peak U.S. sales of $500 million by 2028. This acquisition accelerates Alkermes’s entry into the sleep space, adding a marketed product to its pipeline and establishing direct commercial infrastructure for future launches.

Revenue from Alkermes’s legacy products enabled a 32% year-over-year increase in Lybalvi sales in the first nine months of fiscal 2023, with gross-to-net deductions improving by 150 basis points. These strong cash flows are supporting a more than 25% increase in R&D investment, targeting three late-stage programs beyond the sleep franchise. The company expects to maintain operational profitability, with adjusted EBITDA margins of approximately 15% for the full year, even as it ramps up clinical activities.

The Vibrance-2 trial enrolled 220 patients with type 1 and type 2 narcolepsy and demonstrated a statistically significant increase of 45 minutes in median total sleep time versus placebo (p<0.01), along with a favorable safety profile. Concurrently, alixorexton’s Phase 2 study in idiopathic hypersomnia showed a 60% responder rate (≥50% reduction in daytime sleep episodes). In recognition of these data, the FDA granted Breakthrough Therapy designation for the narcolepsy indication, streamlining the path to potential approval and significantly reducing regulatory risk.